← Back to Search

Microbial Ecosystem Therapeutic

MET-2 20 g for Anxiety

Phase 2
Waitlist Available
Led By Roumen Milev, MD/PhD
Research Sponsored by NuBiyota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to provide informed consent.
Not pregnant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline vs. week 6
Awards & highlights

Study Summary

To measure the effects of Microbial Ecosystem Therapeutics (MET)-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety

Eligible Conditions
  • Depression
  • Anxiety

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline vs. week 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline vs. week 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Anxiety Symptoms
Mental Depression

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MET-2 20 gExperimental Treatment1 Intervention
Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
Group II: PlaceboPlacebo Group1 Intervention
Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MET-2
2017
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

NuBiyotaLead Sponsor
8 Previous Clinical Trials
181 Total Patients Enrolled
Roumen Milev, MD/PhDPrincipal InvestigatorQueens University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~15 spots leftby Mar 2025